News ReleaseView printer-friendly version << Back
AcelRx Pharmaceuticals Announces Commentary in Practical Pain Management on Previously Published Clinical Data on Preoperative Administration of DSUVIA®
The commentary is by three national thought-leaders in the field of pharmacy, Dr.
"We are pleased with the post-approval data and the peer-reviewed commentary that continue to illustrate physiologic and economic rationales for DSUVIA's use in acute pain management in medically supervised settings," said Dr. Pamela Palmer, AcelRx Chief Medical Officer and co-founder. "With an increasing focus on opioid stewardship, DSUVIA is well-suited to effectively manage acute pain while demonstrating in this study the ability to reduce the overall exposure to opioids and contribute to the reduced cost of patient care."
The Tvetenstrand and Wolff study compared a prospective group of patients with preoperative dosing of a single sublingual DSUVIA tablet to a historical control group receiving standard intravenous (IV) opioid administration for same-day general surgery procedures. A total of 127 patients were evaluated in the study, with the following key findings:
- Discharge from the PACU occurred 34% faster than control group.
- Significantly fewer DSUVIA-treated patients required intraoperative IV opioids following preoperative dosing with DSUVIA compared with the control group.
- DSUVIA patients received a significantly lower preoperative and intraoperative mean opioid dose relative to control group.
- Fewer DSUVIA-treated patients required any postoperative opioid with overall opioid utilization being reduced by over 50% with DSUVIA use throughout the perioperative setting.
- Significantly fewer patients in the DSUVIA group received adrenergic agonists for hemodynamic instability and IV acetaminophen for pain.
- Overall, the preoperative administration of DSUVIA resulted in significant reductions in opioid use during outpatient surgery and facilitated shorter PACU stays.
Limitations of the Tvetenstrand and Wolff study include that it was an open-label study, the retrospective nature of the control group, and the focus on only general surgery patients. AcelRx did not provide funding for the conduct of the Tvetenstrand and Wolff study but did fund medical writing support. AcelRx did not provide any compensation to the authors for the commentary. Drs. Tvetenstrand, Fudin and Dasta are paid consultants of AcelRx.
About DSUVIA (sufentanil sublingual tablet), 30 mcg
DSUVIA®, known as DZUVEO™ in
The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration.
View original content to download multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-announces-commentary-in-practical-pain-management-on-previously-published-clinical-data-on-preoperative-administration-of-dsuvia-301175809.html
Media Contacts: Theresa Dolge, Evoke, 215-928-2748, email@example.com, or Lindsay Barnes, Evoke, 215-928-2194, firstname.lastname@example.org; or Investor Contacts: Raffi Asadorian, CFO, AcelRx, email@example.com; or Brian Korb, Solebury Trout, 646-378-2923, firstname.lastname@example.org